Fate Therapeutics (FATE) Other Non Operating Income (2012 - 2025)
Fate Therapeutics' (FATE) quarterly Other Non Operating Income came in at $2.5 million in Q3 2025, down 47.12% YoY from $4.7 million in Q3 2024, and up 4870.0% on a QoQ basis from $50000.0 in Q2 2025.
Fate Therapeutics (FATE) Other Non Operating Income (2012 - 2025) Analysis & Trends
Fate Therapeutics (FATE) has 14 years of Other Non Operating Income data on file, last reported at $2.5 million in Q3 2025.
- Quarterly Other Non Operating Income fell 47.12% year-over-year to $2.5 million in Q3 2025, while the trailing twelve-month figure through Mar 2026 was $2.5 million (down 87.37% YoY) and the FY2025 annual result came in at $93000.0, down 98.43% from the prior year.
- Other Non Operating Income climbed to $2.5 million in Q3 2025, from $50000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $26.1 million in Q4 2022 to a low of -$15.7 million in Q4 2023.
- A 5-year average of $4.9 million and a median of $4.9 million in 2021 frame the typical range for Other Non Operating Income.
- The widest YoY moves for Other Non Operating Income: up 3972.67% in 2023, down 160.22% in 2023.
- Tracing FATE's Other Non Operating Income over 5 years: stood at $4.8 million in 2021, then surged by 439.93% to $26.1 million in 2022, then plunged by 160.22% to -$15.7 million in 2023, then soared by 132.07% to $5.1 million in 2024, then plunged by 50.8% to $2.5 million in 2025.
- The last three Other Non Operating Income figures came in at $2.5 million (Q3 2025), $50000.0 (Q2 2025), and $3.7 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Fate Therapeutics | 298.82 Mn | 298.82 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 2.49 Mn |
| Jun 30, 2025 | 50,000.00 |
| Mar 31, 2025 | 3.66 Mn |
| Dec 31, 2024 | 5.05 Mn |
| Sep 30, 2024 | 4.70 Mn |
| Jun 30, 2024 | 6.66 Mn |
| Mar 31, 2024 | 309,000.00 |
| Dec 31, 2023 | -15.75 Mn |
| Sep 30, 2023 | 6.11 Mn |
| Jun 30, 2023 | 5.04 Mn |
| Mar 31, 2023 | 9.71 Mn |
| Dec 31, 2022 | 26.15 Mn |
| Sep 30, 2022 | 150,000.00 |
| Jun 30, 2022 | 7.00 Mn |
| Mar 31, 2022 | 8.78 Mn |
| Dec 31, 2021 | 4.84 Mn |
| Sep 30, 2021 | 11.32 Mn |
| Mar 31, 2021 | 1.12 Mn |
| Dec 31, 2020 | -19.71 Mn |
| Sep 30, 2020 | -27.20 Mn |